Supporting Information

	CLL/SLL	MCL	WM	FL	MZL	Total
Response Category	(<i>n=</i> 9)	(<i>n</i> =2)	(<i>n</i> =2)	(<i>n</i> =26)	(<i>n</i> =5)	(<i>N</i> =44)
Time to response, months*						
n	9	1	1	12	0	23
Median	2.8	2.8	2.8	2.8		2.8
Min, max	2.7–2.9	2.8–2.8	2.8–2.8	2.6–16.4		2.6–16.4

Table S1. Time to response in Chinese patients with relapsed/refractory B-cell malignancies.

*Time to response is summarized for responders (ie, those who achieved an overall response)


only.

Table S2. Patients with AEs leading to dose interruption.

Patient	AE leading to dose	Outcome	Recurrence after restarting
number	interruption		treatment
			(Yes/No/ Not available)
1	Grade 3 cholesterin granuloma	Resolved	No
	of middle ear		
2	Grade 4 neutropenia	Resolved	Yes, recurred 3.5 months after
			treatment re-initiation. But
			latter event resolved without
			dose interruption
3	Grade 3 febrile neutropenia	Resolved	No

4	Grade 3 purpura	Resolving	Not available. Treatment was	
			not restarted due to disease	
			progression	
5	Grade 2 cough and Grade 1	Resolved	No	
	productive cough			
6	Grade 3 anemia	Resolving	Not available. Treatment was	
			not restarted due to disease	
			progression	
7	Grade 1 leukopenia and Grade	Grade 1	No. Treatment was	
	3 neutropenia	leukopenia	discontinued very soon after re-	
		didn't resolve,	initiation due to disease	
		and Grade 3	progression	
		neutropenia		
		was resolving		
8	Grade 3 anemia	Resolved	Not available. Treatment was	
			not restarted due to disease	
			progression	

Figure S1. Mutational landscape of 14 zanubrutinib-progressive patients. A NGS panel that included 175 hematological malignancy-related genes, and a NGS panel containing 475 lymphoma-related genes were tested in 3 and 11 samples, respectively. All the genes listed in the heatmap were detectable by the lymphoma-related genes panel; three genes (*ATP6V182, CYLD*, *DDX3X*) were not included in the hematological malignancy-related genes panel. BOR, best



overall response; CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; INV,

investigator; MZL, marginal zone lymphoma; WM, Waldenström's macroglobulinemia.